CD8A and neoplasm: Notably, combining hypofractionated RT with CAR‐T cell therapy has demonstrated synergistic potential: preclinical observations indicated that RT enhances the infiltration and activity of CD3+ and CD8+ T cells within the TME, while also upregulating cytotoxic CD107+ T cells, a marker of enhanced degranulation and tumor cell killing [48].